Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973397 | 0.85 | CHRNA7 (0.55) | CHRNA7ABL1BCR | |
| SCHEMBL30495906 | 0.84 | MEN1 (0.63) | MEN1THRBRAB9AKMT2APDPK1 | |
| SCHEMBL20188128 | 0.82 | CCNA2 (0.52) | MEN1THRBRAB9AKMT2A | |
| SCHEMBL3970683 | 0.81 | ABL1 (0.59) | CHRNA7ABL1BCR | |
| SCHEMBL3977569 | 0.80 | CCNT1 (0.60) | CHRNA7ABL1BCR | |
| SCHEMBL13658283 | 0.78 | MEN1 (0.63) | CHRNA7MEN1THRBRAB9AKMT2A | |
| SCHEMBL8997799 | 0.78 | MEN1 (0.63) | CHRNA7MEN1THRBRAB9AKMT2A | |
| SCHEMBL2721728 | 0.77 | CA12 (0.59) | MEN1KMT2AHTT | |
| SCHEMBL30568377 | 0.76 | SCN9A (0.61) | CHRNA7ABL1BCR | |
| SCHEMBL16343865 | 0.76 | RAB9A (0.64) | MEN1THRBRAB9AKMT2APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613595-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-01 | — | — | EP | disclosed |
| EP-1613595-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-11 | — | — | EP | disclosed |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2004089286-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | ABL1, BCR, PDGFRA | CHRNA7 4215/4885MEN1 3873/4885THRB 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.